Synedica Semaglutide GLP-1 Pen Kit

What Semaglutide Is

Semaglutide is a 31-amino-acid analogue of human glucagon-like peptide-1 (GLP-1), modified with an amino-isobutyric acid substitution for resistance to DPP-4 breakdown and a C18 fatty-diacid side chain that binds reversibly to albumin, extending its half-life to roughly a week. This makes it structurally and pharmacokinetically distinct from short unmodified research peptides such as BPC-157 or GHK-Cu. It carries CAS number 910463-68-2, molecular formula C187H291N45O59, and a molecular weight of approximately 4,113.6 g/mol.

As a GLP-1 receptor agonist, semaglutide is studied for its effects on appetite regulation, gastric emptying, and glucose-dependent insulin secretion — mechanisms relevant to metabolic research rather than a claim about what this listing does for any individual.

What Current Research Says

The best-known clinical data on semaglutide comes from the STEP and SUSTAIN trial programmes. STEP 1 (Wilding et al., 2021, New England Journal of Medicine) randomised 1,961 adults with overweight or obesity to once-weekly semaglutide 2.4mg or placebo for 68 weeks; the semaglutide group had a mean body-weight change of −14.9% versus −2.4% with placebo, an estimated treatment difference of −12.4 percentage points. The SUSTAIN trial programme separately evaluated semaglutide for type 2 diabetes at lower doses.

These are clinical trial results for the licensed pharmaceutical product administered under medical supervision at a defined, regulated dose — they describe what has been studied about the active substance, not a claim about this unlicensed research-use listing, which is not administered, supervised, or dosed in the way the trial protocol specifies.

Regulatory Status in the UK

Semaglutide holds MHRA marketing authorisations as Ozempic (type 2 diabetes) and Wegovy (weight management), both Prescription Only Medicines, with Rybelsus as an oral form. This listing is not any of those products. It is an unlicensed research-use vial of the same active substance, sold outside the pharmacy and prescriber system — with no MHRA batch release, no prescriber oversight, and no verified sterility or dosing accuracy.

The MHRA's November 2023 Drug Safety Update reported 369 falsified Ozempic pens seized in the UK by October 2023 (up from zero before January 2023), 16 Yellow Card adverse-event reports by 20 November 2023, and five confirmed cases where pens were relabelled with insulin instead of semaglutide or liraglutide, resulting in hospitalisation for hypoglycaemic shock. That warning concerned falsified branded pens specifically, not research-use listings — but it illustrates the same underlying risk that applies to any semaglutide-type product obtained outside the regulated supply chain: there is no independent guarantee that the vial contains what the label says. This listing is supplied strictly for laboratory and in-vitro research use, is not licensed under the Human Medicines Regulations 2012 (SI 2012/1916), and has not been assessed by the MHRA for safety or efficacy under this listing.

Specifications

Purity, Batch Testing and Certificate of Analysis Standards

Every Synedica Semaglutide GLP-1 Pen Kit unit offered for sale is supplied with third-party analytical documentation confirming peptide identity and purity, the analytical method used (typically HPLC or mass spectrometry), the batch or lot number, and the issuing laboratory. Given the MHRA's documented findings of pens mislabelled with the wrong active substance entirely, verifying that a listing's CAS number, molecular formula, and COA are independently checkable matters more for semaglutide than for peptides with no licensed counterpart. See our contact page to request a Certificate of Analysis for a specific batch.

Sourcing and Verification

Before ordering, check that a listing states research-use status clearly rather than implying it is a substitute for Ozempic, Wegovy, or a prescriber-supervised weight-management programme, that batch documentation is offered rather than promised only “on request,” and that the compound's identity (CAS number, molecular formula) is independently verifiable against a source such as PubChem. Synedica Semaglutide GLP-1 Pen Kit is offered for sale on this basis, with documentation available per batch. Researchers examining other GLP-1 and metabolic-research peptides may also find Synedica Retatrutide 40mg and Synedica Tirzepatide 40mg relevant, and the full catalogue is browsable on the research products page.